MS
LENZ

Maven Securities’s LENZ Therapeutics LENZ Stock Holding History

Maven Securities’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,429
Closed -$26.2K – 1043
2023
Q4 		$26.2K Buy
+1,429
New +$23.6K ﹤0.01% 903
2021
Q3 		– Sell
-1,786
Closed -$389K – 1307
2021
Q2 		$389K Buy
+1,786
New +$311K 0.02% 762

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Maven Securities's LENZ Position: Q1 2024 in Review

Maven Securities sold out of LENZ Therapeutics (LENZ) in Q1 2024, closing a stake of 1,429 shares — an estimated $26.2K sold.

Maven Securities first reported a position in LENZ in Q2 2021 and held it in 2 quarters. The position peaked at $389K in Q2 2021. 55 funds tracked by Wall St. Rank hold LENZ as of Q1 2024.

  • Maven Securities reported no remaining LENZ Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Maven Securities sold 1,429 LENZ Therapeutics shares in Q1 2024, an estimated $26.2K.
  • Maven Securities first reported a position in LENZ Therapeutics in Q2 2021 and held it in 2 quarters.
  • Maven Securities's LENZ Therapeutics position peaked at $389K in Q2 2021.
  • 55 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2024.

Based on Maven Securities's 13F filing for Q1 2024, filed 14 May 2024.